Bank of England publishes its latest insights into the economic impact of Brexit on British real productivity, capital investment, and labor supply.

Olivia London

2018-12-03 10:40:00 Mon ET

Bank of England publishes its latest insights into the economic impact of Brexit on British real productivity, capital investment, and labor supply as of 2018Q4. With a cautious tone, the U.K. central bank suggests that its future interest rate decisions would depend on the trade terms of the U.K. departure from the European Union. With Brexit, economic policy uncertainty weighs on U.K. productivity and economic growth, and future lower immigration may adversely affect British labor supply and real macro performance.

Brexit imposes financial constraints on both capital investment and labor supply that may reinforce the current economic slowdown in the U.K. in light of the neutral interest rate at which the British economy grows without much inflationary pressure. Bank of England Governor Mark Carney acknowledges the brutal fact that Britain is not fully prepared for a cliff-edge Brexit. Carney predicts that the U.K. economy may shrink by 8% in mid-2019 in the worse-case scenario where Britain leaves the European Union free trade bloc with no deal and no transition period to smooth the arcane process. When push comes to shove, the law of inadvertent consequences counsels caution.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

A physicist derives a mathematical formula for success.

Chanel Holden

2019-03-07 12:39:00 Thursday ET

A physicist derives a mathematical formula for success.

A physicist derives a mathematical formula that success equates the product of both personal quality and the potential value of a random idea. As a Northeas

+See More

International trade, immigration, and elite-mass conflict

Jacob Miramar

2023-12-09 08:28:00 Saturday ET

International trade, immigration, and elite-mass conflict

International trade, immigration, and elite-mass conflict The elite model portrays public policy as a reflection of the interests and values of elites. I

+See More

Global stock market investors foresee the harbinger of a major economic downturn.

Monica McNeil

2019-09-17 08:33:00 Tuesday ET

Global stock market investors foresee the harbinger of a major economic downturn.

Global stock market investors foresee the harbinger of a major economic downturn. Many stock market investors become anxious due to negative term spreads an

+See More

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Rose Prince

2018-02-27 09:35:00 Tuesday ET

Fed's new chairman Jerome Powell testifies before Congress for the first time.

Fed's new chairman Jerome Powell testifies before Congress for the first time. He vows to prevent price instability for U.S. consumers, firms, and finan

+See More

Santa-Barbara political economy professor Benjamin Cohen proposes new fiscal stimulus to complement the current low-interest-rate monetary policy.

Daphne Basel

2019-08-28 14:46:00 Wednesday ET

Santa-Barbara political economy professor Benjamin Cohen proposes new fiscal stimulus to complement the current low-interest-rate monetary policy.

Santa-Barbara political economy professor Benjamin Cohen proposes new fiscal stimulus to complement the current low-interest-rate monetary policy. Cohen fin

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More